Quzyttir is owned by Jdp.
Quzyttir contains Cetirizine Hydrochloride.
Quzyttir has a total of 5 drug patents out of which 0 drug patents have expired.
Quzyttir was authorised for market use on 04 October, 2019.
Quzyttir is available in solution;intravenous dosage forms.
Quzyttir can be used as method of treatment in patients with concomitant angioedema, method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria, treatment of acute urticaria.
The generics of Quzyttir are possible to be released after 28 February, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) | |
US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 4, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...
Dosage: SOLUTION;INTRAVENOUS
11
United States
1
Canada
1
Spain
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic